Literature DB >> 22098466

Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching.

Kirk E Hevener1, Shahila Mehboob, Pin-Chih Su, Kent Truong, Teuta Boci, Jiangping Deng, Mahmood Ghassemi, James L Cook, Michael E Johnson.   

Abstract

Enoyl-acyl carrier protein (ACP) reductase, FabI, is a key enzyme in the bacterial fatty acid biosynthesis pathway (FAS II). FabI is an NADH-dependent oxidoreductase that acts to reduce enoyl-ACP substrates in a final step of the pathway. The absence of this enzyme in humans makes it an attractive target for the development of new antibacterial agents. FabI is known to be unresponsive to structure-based design efforts due to a high degree of induced fit and a mobile flexible loop encompassing the active site. Here we discuss the development, validation, and careful application of a ligand-based virtual screen used for the identification of novel inhibitors of the Francisella tularensis FabI target. In this study, four known classes of FabI inhibitors were used as templates for virtual screens that involved molecular shape and electrostatic matching. The program ROCS was used to search a high-throughput screening library for compounds that matched any of the four molecular shape queries. Matching compounds were further refined using the program EON, which compares and scores compounds by matching electrostatic properties. Using these techniques, 50 compounds were selected, ordered, and tested. The tested compounds possessed novel chemical scaffolds when compared to the input query compounds. Several hits with low micromolar activity were identified and follow-up scaffold-based searches resulted in the identification of a lead series with submicromolar enzyme inhibition, high ligand efficiency, and a novel scaffold. Additionally, one of the most active compounds showed promising whole-cell antibacterial activity against several Gram-positive and Gram-negative species, including the target pathogen. The results of a preliminary structure-activity relationship analysis are presented.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098466      PMCID: PMC3266168          DOI: 10.1021/jm201168g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  51 in total

Review 1.  Community benchmarks for virtual screening.

Authors:  John J Irwin
Journal:  J Comput Aided Mol Des       Date:  2008-02-14       Impact factor: 3.686

Review 2.  Antibacterial targets in fatty acid biosynthesis.

Authors:  H Tonie Wright; Kevin A Reynolds
Journal:  Curr Opin Microbiol       Date:  2007-08-17       Impact factor: 7.934

3.  1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Authors:  D A Heerding; G Chan; W E DeWolf; A P Fosberry; C A Janson; D D Jaworski; E McManus; W H Miller; T D Moore; D J Payne; X Qiu; S F Rittenhouse; C Slater-Radosti; W Smith; D T Takata; K S Vaidya; C C Yuan; W F Huffman
Journal:  Bioorg Med Chem Lett       Date:  2001-08-20       Impact factor: 2.823

4.  Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence.

Authors:  Aiping Qin; David W Scott; Barbara J Mann
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

Review 5.  Tularemia: current diagnosis and treatment options.

Authors:  Matthew J Hepburn; Andrew J H Simpson
Journal:  Expert Rev Anti Infect Ther       Date:  2008-04       Impact factor: 5.091

6.  Functional expression of Francisella tularensis FabH and FabI, potential antibacterial targets.

Authors:  Lisa Wen; Jennifer N Chmielowski; Kelsey C Bohn; Jenq-Kuen Huang; Yam N Timsina; Phanichand Kodali; Ashish K Pathak
Journal:  Protein Expr Purif       Date:  2008-12-06       Impact factor: 1.650

7.  Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens.

Authors:  Sophie Brinster; Gilles Lamberet; Bart Staels; Patrick Trieu-Cuot; Alexandra Gruss; Claire Poyart
Journal:  Nature       Date:  2009-03-05       Impact factor: 49.962

8.  Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus.

Authors:  Hua Xu; Todd J Sullivan; Jun-ichiro Sekiguchi; Teruo Kirikae; Iwao Ojima; Christopher F Stratton; Weimin Mao; Fernando L Rock; M R K Alley; Francis Johnson; Stephen G Walker; Peter J Tonge
Journal:  Biochemistry       Date:  2008-03-13       Impact factor: 3.162

Review 9.  Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Authors:  Hao Lu; Peter J Tonge
Journal:  Acc Chem Res       Date:  2008-01       Impact factor: 22.384

10.  Identification of a chemical probe for NAADP by virtual screening.

Authors:  Edmund Naylor; Abdelilah Arredouani; Sridhar R Vasudevan; Alexander M Lewis; Raman Parkesh; Akiko Mizote; Daniel Rosen; Justyn M Thomas; Minoru Izumi; A Ganesan; Antony Galione; Grant C Churchill
Journal:  Nat Chem Biol       Date:  2009-02-22       Impact factor: 15.040

View more
  23 in total

1.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

2.  Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques.

Authors:  Jinhong Ren; Tina L Mistry; Pin-Chih Su; Shahila Mehboob; Robel Demissie; Leslie Wo-Mei Fung; Arun K Ghosh; Michael E Johnson
Journal:  Bioorg Med Chem Lett       Date:  2018-04-22       Impact factor: 2.823

3.  Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.

Authors:  Yan-Yan Zhang; Yong Liu; Shahila Mehboob; Jin-Hua Song; Teuta Boci; Michael E Johnson; Arun K Ghosh; Hyunyoung Jeong
Journal:  Xenobiotica       Date:  2013-10-30       Impact factor: 1.908

4.  Shape similarity guided pose prediction: lessons from D3R Grand Challenge 3.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  J Comput Aided Mol Des       Date:  2018-08-06       Impact factor: 3.686

5.  Prospective evaluation of shape similarity based pose prediction method in D3R Grand Challenge 2015.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  J Comput Aided Mol Des       Date:  2016-08-02       Impact factor: 3.686

6.  A pose prediction approach based on ligand 3D shape similarity.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  J Comput Aided Mol Des       Date:  2016-07-05       Impact factor: 3.686

7.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 8.  Structural approaches to pathway-specific antimicrobial agents.

Authors:  Michael E Johnson; Leslie W-M Fung
Journal:  Transl Res       Date:  2020-02-06       Impact factor: 7.012

9.  Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.

Authors:  Tina L Mistry; Lena Truong; Arun K Ghosh; Michael E Johnson; Shahila Mehboob
Journal:  ACS Infect Dis       Date:  2016-10-27       Impact factor: 5.084

10.  Comparison of radii sets, entropy, QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies of F. tularensis enoyl-ACP reductase (FabI).

Authors:  Pin-Chih Su; Cheng-Chieh Tsai; Shahila Mehboob; Kirk E Hevener; Michael E Johnson
Journal:  J Comput Chem       Date:  2015-07-27       Impact factor: 3.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.